A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion.

The 'textbook' approach to determining sample size in a clinical trial has some fundamental weaknesses which we discuss. We describe a new predictive method which takes account of prior clinical opinion about the treatment difference. The method adopts the point of clinical equivalence (determined by interviewing the clinical participants) as the null hypothesis. Decision rules at the end of the study are based on whether the interval estimate of the treatment difference (classical or Bayesian) includes the null hypothesis. The prior distribution is used to predict the probabilities of making the decisions to use one or other treatment or to reserve final judgement. It is recommended that sample size be chosen to control the predicted probability of the last of these decisions. An example is given from a multi-centre trial of superficial bladder cancer.

[1]  H. Raiffa,et al.  Applied Statistical Decision Theory. , 1961 .

[2]  Day Ne.  Two-stage designs for clinical trials. , 1969 .

[3]  Elizabeth C. Hirschman,et al.  Judgment under Uncertainty: Heuristics and Biases , 1974, Science.

[4]  J. Fleiss.  Statistical methods for rates and proportions , 1974 .

[5]  P. Meier,et al.  Statistics and medical experimentation. , 1975, Biometrics.

[6]  A. Feinstein.  XXXIV. The other side of ‘statistical significance’: alpha, beta. delta, and the calculation of sample size , 1975, Clinical pharmacology and therapeutics.

[7]  Robin M. Hogarth,et al.  Cognitive Processes and the Assessment of Subjective Probability Distributions , 1975 .

[8]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[9]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[10]  A. H. Murphy,et al.  Reliability of Subjective Probability Forecasts of Precipitation and Temperature , 1977 .

[11]  Frederick Mosteller,et al.  Statistics and ethics in surgery and anesthesia. , 1977 .

[12]  C. Dunnett,et al.  Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. , 1977, Biometrics.

[13]  M J Healy.  New methodology in clinical trials. , 1978, Biometrics.

[14]  D. Sackett,et al.  Controversy in counting and attributing events in clinical trials. , 1979, The New England journal of medicine.

[15]  J. Herson,et al.  Predictive probability early termination plans for phase II clinical trials. , 1979, Biometrics.

[16]  A. Spriet,et al.  When can 'non significantly different' treatments be considered as 'equivalent'? , 1979, British Journal of Clinical Pharmacology.

[17]  P. Meier.  Terminating a trial—the ethical problem , 1979, Clinical pharmacology and therapeutics.

[18]  B. W. Brown,et al.  Statistical controversies in the design of clinical trials—Some personal views* , 1980 .

[19]  A. Dempster,et al.  A Bayesian approach to bioequivalence for the 2 x 2 changeover design. , 1981, Biometrics.

[20]  B. Armstrong,et al.  Assessing clinical trials—trial size , 1981 .

[21]  M S Thompson,et al.  Decision-Analytic Determination of Study Size , 1981, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  S. Gore.  Statistics in question. Assessing clinical trials--trial size. , 1981, British medical journal.

[23]  J. Lachin.  Introduction to sample size determination and power analysis for clinical trials. , 1981, Controlled clinical trials.

[24]  B W Brown,et al.  KSTAGE: an interactive computer program for designing phase II clinical trials using predictive probability. , 1982, Computers and biomedical research, an international journal.

[25]  K McPherson,et al.  On choosing the number of interim analyses in clinical trials. , 1982, Experientia. Supplementum.

[26]  D L DeMets,et al.  An aid to data monitoring in long-term clinical trials. , 1982, Controlled clinical trials.

[27]  A Donner,et al.  A Bayesian approach to the interpretation of subgroup results in clinical trials. , 1982, Journal of chronic diseases.

[28]  W C Blackwelder,et al.  "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.

[29]  C. Bulpitt.  Randomised Controlled Clinical Trials , 1983, Developments in Biostatistics and Epidemiology.

[30]  D. Spiegelhalter,et al.  The Assessment of the Subjective Opinion and its Use in Relation to Stopping Rules for Clinical Trials , 1983 .

[31]  P. Macaskill,et al.  Stopping rules for clinical trials. , 1983, Statistics in medicine.

[32]  B. Turnbull,et al.  Repeated confidence intervals for group sequential clinical trials. , 1984, Controlled clinical trials.

[33]  P. Armitage,et al.  Controversies and achievements in clinical trials. , 1984, Controlled clinical trials.

[34]  P. Macaskill,et al.  Stopping rules for clinical trials incorporating clinical opinion. , 1984, Biometrics.

[35]  A Donner,et al.  Approaches to sample size estimation in the design of clinical trials--a review. , 1984, Statistics in medicine.

[36]  M. Palmer.  Clinical Trials: A Practical Approach , 1985 .

[37]  D. Spiegelhalter,et al.  Monitoring clinical trials: conditional or predictive power? , 1986, Controlled clinical trials.

[38]  P K Andersen,et al.  Conditional power calculations as an aid in the decision whether to continue a clinical trial. , 1987, Controlled clinical trials.